Premature ejaculation is a male sexual dysfunction characterized by short, easily stimulated ejaculation that occurs always or nearly always before or within one minute of vaginal penetration.
It is involuntarily controlled and causes negative personal consequences like distress, frustration and avoidance of sexual intimacy.
Exact etiology and risk factors are unknown.
Short, easily stimulated ejaculation that occurs always or nearly always before or within about 1 minute of vaginal penetration or a clinically significant and bothersome reduction in latency time, often to about 3 minutes or less
Either present from the first sexual experience or following a new bothersome change in ejaculatory latency
Causes negative personal consequences eg distress, bother, frustration, avoidance of sexual intimacy and interpersonal difficulty
Most common male sexual dysfunction with prevalence not affected by age
More common in younger men
Unknown exact etiology with few data to support the following suggested biological and psychological hypotheses including:
5-HT receptor dysfunction
Risk factors include:
Genetic influences (lifelong PE)
Prostatic inflammation and chronic bacterial prostatitis (acquired PE)
Hormonal aberrations or thyroid hormone disorders
Poor overall health status and obesity
Psychological factors that may precipitate PE are historical
factors (eg sexual abuse, attitude towards sex in the home), individual
psychological factors (eg body image, depression, performance anxiety)
or relationship factors (eg intimacy, anger)
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.